Damora Therapeutics, Inc.

Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing novel small-molecule therapeutics for cancer and liver diseases. The company is focused on product candidates GB1211 and GB3226, targeting areas with high unmet medical need and no disease-modifying treatment options.

12.98

12.98

— Damora Therapeutics, Inc.
%
GB322650% Preclinical small-molecule program being advanced toward IND submission and later clinical development.
GB121135% Clinical-stage product candidate in the company's oncology and liver disease pipeline.
Discovery and pipeline expansion10% Research, in-licensing and development of additional product candidates and technologies.
Future commercialization5% Potential sales, marketing, medical affairs and distribution activities if candidates are approved.

Damora does not currently sell approved products; its near-term 'customers' are regulators, clinical trial...

  • Regulatory authoritiesprimary

    FDA, EMA and other agencies review preclinical and clinical data and determine whether programs can advance.

  • CRO and CMO partnersprimary

    Contract research and manufacturing organizations provide trial execution, testing and drug supply.

  • Patients with oncology and liver diseasesecondary

    Future end users of approved therapies if GB1211, GB3226 or other candidates reach market.

  • Physicians and hospitalssecondary

    Clinical decision-makers who would adopt the therapies based on efficacy, safety and convenience.

  • Third-party payorssecondary

    Commercial and government payors that would determine access through coverage and reimbursement.

Damora is headquartered in the United States and its development work is centered on U.S...

  • •United States is the core operating and regulatory base
  • •FDA is central to GB3226 IND and clinical development plans
  • •EMA and other foreign regulators may matter for future expansion
  • •International CRO/CMO supply chains create cross-border execution risk
  • •Trade policy and tariffs can raise input and manufacturing costs

The company is prioritizing GB3226 and GB1211, with GB3226 expected to advance through preclinical work and toward an...

01
Advance GB3226 to IND submissionshort-term

This is the clearest near-term value-creation milestone and supports progression into clinical development.

02
Fund the pipeline through additional capitalshort-term

The company expects substantial additional funding needs and has going-concern risk without financing.

03
Build development and commercialization infrastructuremedium-term

Clinical-stage biotech requires regulatory, manufacturing and commercial capabilities before launch.

04
Protect intellectual property and secure partnershipsmedium-term

Pipeline value depends on patent protection, exclusivity and access to external expertise and capital.

Damora is a pre-revenue biotech with substantial going-concern and financing risk because it must fund long development...

critical

Insufficient financing and going-concern risk

The company states it will require substantial additional capital and may need to cut or stop programs if funding is unavailable.

Scope
All development programs and corporate continuity
Materiality
high
high

Clinical development and regulatory failure

Product candidates must succeed in preclinical and clinical studies and obtain FDA/other approvals before commercialization.

Scope
GB3226, GB1211 and future pipeline assets
Materiality
high
high

Outsourced manufacturing and supply-chain disruption

The company relies on third-party manufacturers and international inputs for preclinical and clinical supply.

Scope
API supply, trial materials and future scale-up
Materiality
high
high

Intellectual property and competition risk

Value depends on maintaining patents, exclusivity and freedom to operate against competing therapies and third-party IP claims.

Scope
Pipeline protection and future commercialization
Materiality
high
medium

Trade policy and geopolitical risk

Tariffs, import restrictions and geopolitical instability can raise costs and delay research or manufacturing activities.

Scope
Reagents, equipment and outsourced development
Materiality
medium
Research and development accruals
Can materially shift quarterly operating loss and working capital
Going-concern assessment
Important for liquidity analysis and capital structure risk
Deferred tax assets and valuation allowance
Can affect tax benefit recognition and equity
Clinical trial cost timing
Reduces comparability of period-to-period R&D spend

Tyra Biosciences, Inc.

TYRA · Pharmaceutical Preparations

Kymera Therapeutics, Inc.

KYMR · Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

: 28/04/2026